Literature DB >> 23541899

Implications for Interleukin-33 in solid organ transplantation.

Quan Liu1, Hēth R Turnquist.   

Abstract

Interleukin(IL)-33 is a member of the IL-1 cytokine family that has been attributed T helper (Th) type 2 immunity-promoting capacity. However, new studies indicate that IL-33 is a multifunctional protein that acts as transcriptional/signaling repressor, functions as an alarmin alerting the immune system to necrosis, as well as serves as a cytokine that targets cells expressing ST2, the IL-33 receptor. Interestingly, IL-33 is also emerging as a pleiotropic cytokine. Depending on the innate or adaptive immune cells targeted by IL-33, it can not only promote type 2, but also IFN-γ dominated type 1 immunity. In addition, IL-33 expands regulatory T cells. In this review, we assimilate the current knowledge of IL-33 immunobiology and discuss how IL-33 may mediate such diverse roles in the immune response to pathogens and development of immune-mediated pathologies. The function of IL-33 in shaping alloimmune responses to transplanted organs is poorly explored, but a particularly beneficial role of IL-33 in experimental heart transplant models is summarized. Finally, given the implication of IL-33 in pathologies of the lung and intestine, we discuss how IL-33 may contribute to the comparatively poor outcomes following transplantation of these two organs.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23541899      PMCID: PMC3640740          DOI: 10.1016/j.cyto.2013.02.026

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  136 in total

1.  Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

Authors:  Herwig-Ulf Meier-Kriesche; Jesse D Schold; Titte R Srinivas; Bruce Kaplan
Journal:  Am J Transplant       Date:  2004-03       Impact factor: 8.086

Review 2.  Innate lymphoid cells: emerging insights in development, lineage relationships, and function.

Authors:  Hergen Spits; Tom Cupedo
Journal:  Annu Rev Immunol       Date:  2012-01-06       Impact factor: 28.527

Review 3.  Plasticity of CD4+ T cell lineage differentiation.

Authors:  Liang Zhou; Mark M W Chong; Dan R Littman
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

4.  Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain.

Authors:  Mélanie Pichery; Emilie Mirey; Pascale Mercier; Emma Lefrancais; Arnaud Dujardin; Nathalie Ortega; Jean-Philippe Girard
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

5.  Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis.

Authors:  Luca Pastorelli; Rekha R Garg; Sharon B Hoang; Luisa Spina; Benedetta Mattioli; Melania Scarpa; Claudio Fiocchi; Maurizio Vecchi; Theresa T Pizarro
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

Review 6.  The immune response in atherosclerosis: a double-edged sword.

Authors:  Göran K Hansson; Peter Libby
Journal:  Nat Rev Immunol       Date:  2006-06-16       Impact factor: 53.106

Review 7.  Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients.

Authors:  S C Jordan; M Toyoda; J Kahwaji; A A Vo
Journal:  Am J Transplant       Date:  2011-01-10       Impact factor: 8.086

8.  Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation.

Authors:  L Fan; H L Benson; R Vittal; E A Mickler; R Presson; A Jo Fisher; O W Cummings; K M Heidler; M R Keller; W J Burlingham; D S Wilkes
Journal:  Am J Transplant       Date:  2011-04-19       Impact factor: 8.086

9.  Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation.

Authors:  Axel M Küchler; Jürgen Pollheimer; Johanna Balogh; Jon Sponheim; Linda Manley; Dag R Sorensen; Paula M De Angelis; Helge Scott; Guttorm Haraldsen
Journal:  Am J Pathol       Date:  2008-09-11       Impact factor: 4.307

10.  Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.

Authors:  Gaby Palmer; Dominique Talabot-Ayer; Céline Lamacchia; Dean Toy; Christian A Seemayer; Sébastien Viatte; Axel Finckh; Dirk E Smith; Cem Gabay
Journal:  Arthritis Rheum       Date:  2009-03
View more
  10 in total

1.  Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.

Authors:  Xin Gao; Xuefeng Wang; Qianting Yang; Xin Zhao; Wen Wen; Gang Li; Junfeng Lu; Wenxin Qin; Yuan Qi; Fang Xie; Jingting Jiang; Changping Wu; Xueguang Zhang; Xinchun Chen; Heth Turnquist; Yibei Zhu; Binfeng Lu
Journal:  J Immunol       Date:  2014-11-26       Impact factor: 5.422

2.  The IL-33/ST2 axis augments effector T-cell responses during acute GVHD.

Authors:  Dawn K Reichenbach; Vincent Schwarze; Benjamin M Matta; Victor Tkachev; Elisabeth Lieberknecht; Quan Liu; Brent H Koehn; Dietmar Pfeifer; Patricia A Taylor; Gabriele Prinz; Heide Dierbach; Natalie Stickel; Yvonne Beck; Max Warncke; Tobias Junt; Annette Schmitt-Graeff; Susumu Nakae; Marie Follo; Tobias Wertheimer; Lukas Schwab; Jason Devlin; Simon C Watkins; Justus Duyster; James L M Ferrara; Heth R Turnquist; Robert Zeiser; Bruce R Blazar
Journal:  Blood       Date:  2015-03-26       Impact factor: 22.113

3.  Exogenous interleukin-33 targets myeloid-derived suppressor cells and generates periphery-induced Foxp3⁺ regulatory T cells in skin-transplanted mice.

Authors:  Tania Gajardo; Rodrigo A Morales; Mauricio Campos-Mora; Javier Campos-Acuña; Karina Pino-Lagos
Journal:  Immunology       Date:  2015-06-19       Impact factor: 7.397

4.  IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells.

Authors:  Benjamin M Matta; Jeremy M Lott; Lisa R Mathews; Quan Liu; Brian R Rosborough; Bruce R Blazar; Hēth R Turnquist
Journal:  J Immunol       Date:  2014-09-12       Impact factor: 5.422

5.  Recombinant IL-33 prolongs leflunomide-mediated graft survival by reducing IFN-γ and expanding CD4(+)Foxp3(+) T cells in concordant heart transplantation.

Authors:  Chen Dai; Fang-Na Lu; Ning Jin; Bo Yang; Chang Gao; Bin Zhao; Jia-Zhao Fu; Shi-Fu Hong; Han-Ting Liang; Li-Hong Chen; Zhi-Shui Chen; Jie Chen; Zhong-Quan Qi
Journal:  Lab Invest       Date:  2016-06-13       Impact factor: 5.662

Review 6.  Controlling the burn and fueling the fire: defining the role for the alarmin interleukin-33 in alloimmunity.

Authors:  Quan Liu; Heth R Turnquist
Journal:  Curr Opin Organ Transplant       Date:  2016-02       Impact factor: 2.640

7.  Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD.

Authors:  Benjamin M Matta; Dawn K Reichenbach; Xiaoli Zhang; Lisa Mathews; Brent H Koehn; Gaelen K Dwyer; Jeremy M Lott; Franziska M Uhl; Dietmar Pfeifer; Colby J Feser; Michelle J Smith; Quan Liu; Robert Zeiser; Bruce R Blazar; Hēth R Turnquist
Journal:  Blood       Date:  2016-05-24       Impact factor: 22.113

8.  Elevated ST2 Distinguishes Incidences of Pediatric Heart and Small Bowel Transplant Rejection.

Authors:  L R Mathews; J M Lott; K Isse; A Lesniak; D Landsittel; A J Demetris; Y Sun; D F Mercer; S A Webber; A Zeevi; R T Fischer; B Feingold; H R Turnquist
Journal:  Am J Transplant       Date:  2015-12-11       Impact factor: 8.086

Review 9.  Sterile inflammation in thoracic transplantation.

Authors:  C Corbin Frye; Amit I Bery; Daniel Kreisel; Hrishikesh S Kulkarni
Journal:  Cell Mol Life Sci       Date:  2020-08-17       Impact factor: 9.261

10.  Elevated Circulating Interleukin 33 Levels in Stable Renal Transplant Recipients at High Risk for Cardiovascular Events.

Authors:  Holly Mansell; Mahmoud Soliman; Hamdi Elmoselhi; Ahmed Shoker
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.